DUBLIN--(BUSINESS WIRE)--The "Antiemetics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
During the Last Decades, Extraordinary Technological Advances Have Made Innovations in Most of the Disease Therapies, Including Cancer Therapies, Which Is the Most Common Cause of Emesis
The report details the antiemetic drug market. The analysis highlights current and future market potential for antiemetic drug and presents a detailed review of pipeline drugs, blockbuster drugs, and challenges to market growth. The report also examines disease burden, regulatory environment, novel technologies, and market projections to 2023. Antiemetic drug market drivers, trends and potential regional market opportunities are also covered in this report.
The report details market shares of antiemetic drug class (5-HT3 receptor antagonists, dopamine antagonists, steroid-corticosteroids, benzodiazepines, NK1 receptor antagonist, antihistamines, cannabinoids, and anticholinergic) and geographic market segmentation of overall market; global market share by applications, with special emphasis on developed and underdeveloped geographic regions. For market estimates, data has been provided for 2017, as the base year, 2018 and forecast for 2023.
The Report Includes:
- 21 data tables and 15 additional tables
- Country-specific data and analysis for United States, Canada, Mexico, France, Germany, UK, China, India, Japan, and the Middle East and Africa
- An overview about current and future market potential for antiemetic drugs with special focus on the competitive environment, pipeline drugs and blockbuster drugs
- Coverage of disease burden, regulatory environment, and novel technologies in the antiemetic drugs market
- Detailed description about the vestibular disorder and increasing demand of innovative technology for treatment
- Exploration of the causes of emesis, usage of antiemetics and the types of products available to treat nausea and vomiting by each application segment
- Information about the launching of new drugs in each antiemetic drug class such as 5 HT3 receptor antagonists, dopamine antagonists, NK1 receptor antagonist, and so forth
- Detailed company profiles of major players in the market, including Abbott Laboratories, Daiichi Sankyo Company, Ltd., Merck & Co., Novartis AG, Sanofi Aventis and Teva Pharmaceutical Industries Ltd.
Key Topics Covered:
1 Introduction
2 Summary And Highlights
3 Overview
4 Market And Technology Background
5 Market Breakdown By Drug Class
6 Market Breakdown By Application
7 Market Breakdown By Region
8 Patent Review/New Developments
9 Pipeline Analysis
10 Regulatory Landscape
11 Company Profiles
12 Appendix: Abbreviations
Companies Mentioned
- Abbott Laboratories
- Aphios Corp.
- Astellas Pharma Inc.
- Aurobindo Pharma
- Daiichi Sankyo Company Ltd.
- Eisai Co., Inc.
- F. Hoffmann-La Roche Ag
- Glaxosmithkline Plc
- Helsinn Healthcare Sa
- Heron Therapeutics, Inc.
- IPCA Laboratories, Ltd.
- Kyowa Hakko Kirin Pharma, Inc.
- Merck & Co., Inc.
- Novartis Ag
- Sanofi Aventis
- Tesaro, Inc.
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/llrkk8/antiemetics?w=4
